FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly
The FDA has accepted a supplemental application for Emgality, CGRP inhibitor developed by Eli Lilly.
Therapeutic Area
Therapeutic area intelligence for CGRP Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.